Condition: Mitral Regurgitation · Sponsor: Peijia Medical Technology (Suzhou) Co., Ltd.
To observe and evaluate the safety and efficacy of the HighLife Transcatheter Mitral Valve Replacement System in patients with moderate-severe or severe mitral valve regurgitation through a prospective, multicenter clinical trial using objective performance criteria.
This description comes directly from the study's public registry record.
Kejing Yi · +86-13801858760 · yikejing@peijiamedical.com
Always discuss trial participation with your own doctor first.
| Peiga Medical Technology (Suzhou) Co. | Suzhou, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05610566